BUND FINANCE › Stocks › JNJ
Johnson & Johnson (JNJ)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed
Key stats
Quick technical read
- Price is +2.06% above its 50-day average.
- It is +8.95% above its 200-day average (long-term uptrend).
- It sits at 81% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$78.7B | US$80.0B | US$85.2B | US$88.8B | US$94.2B |
| Net income | US$20.9B | US$17.9B | US$35.2B | US$14.1B | US$26.8B |
| EPS (diluted) | 7.81 | 6.73 | 13.72 | 5.79 | 11.03 |
| Gross margin | 70.3% | 69.3% | 68.8% | 69.1% | 67.9% |
| Operating margin | 26.6% | 26.3% | 27.5% | 24.9% | 27.2% |
| Net margin | 26.5% | 22.4% | 41.3% | 15.8% | 28.5% |
| Free cash flow | US$19.8B | US$17.2B | US$18.2B | US$19.8B | US$19.7B |
| Total debt | US$33.8B | US$39.6B | US$29.3B | US$36.6B | US$47.9B |
| Cash | US$14.5B | US$12.9B | US$21.9B | US$24.1B | US$19.7B |
Compound annual growth: revenue 4.6% · net income 6.5% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 41.3x | 20.4x | 27.1x |
| EV / EBITDA | 25.5x | 16.1x | 16.5x |
| Operating margin | 25.2% | — | 3.6% |
| Net margin | 16.2% | — | -0.0% |
| Debt / equity | 1.42 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice